|Bid||0.00 x 1300|
|Ask||0.00 x 900|
|Day's range||20.88 - 22.81|
|52-week range||9.74 - 27.82|
|Beta (5Y monthly)||2.68|
|PE ratio (TTM)||N/A|
|Earnings date||03 May 2020 - 07 May 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||28.88|
A week ago, Epizyme, Inc. (NASDAQ:EPZM) came out with a strong set of yearly numbers that could potentially lead to a...
Epizyme (EPZM) delivered earnings and revenue surprises of -15.69% and 51.57%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Epizyme Provides Business Update and Reports Fourth Quarter and Full Year 2019 Financial Results
Epizyme, Inc. (Nasdaq: EPZM), a biopharmaceutical company developing novel epigenetic therapies, today announced that management will host a conference call and webcast to discuss its fourth quarter and full year 2019 financial results and present at upcoming investor conferences. Details of the events are below:
Epizyme Announces FDA Acceptance of New Drug Application for Filing with Priority Review for TAZVERIK™ (tazemetostat) for the Treatment of FL
One simple way to benefit from the stock market is to buy an index fund. But if you pick the right individual stocks...
Epizyme (EPZM) gets a significant boost with the approval of Tazverik (tazemetostat) for the treatment of metastatic or locally advanced epithelioid sarcoma.
Epizyme Announces U.S. FDA Accelerated Approval of TAZVERIK™ (tazemetostat) for the Treatment of Patients with Epithelioid Sarcoma
Axsome (AXSM) closes patient randomization in the late-stage study of AXS-05 for addressing patients with treatment resistant depression.
The FDA receives Evoke Pharma's (EVOK) refiling of new drug application for its pipeline candidate Gimoti, which is being developed to treat diabetic gastroparesis.
Puma Biotech (PBYI) focuses on improving sales of its only marketed drug Nerlynx, which is approved for treating breast cancer. The drug's label expansion programs also look promising.
Seattle Genetics' (SGEN) Adcetris registers strong sales in 2019. The company wins an accelerated approval for Padcev to treat urothelial cancer while other pipeline candidates also progress well.
Applied Therapeutics (APLT) soars on positive top-line results from the mid-stage study in adult Galactosemia patients on pipeline candidate, AT-007.
Blueprint Medicines (BPMC) and partner CStone begin dosing in the phase Ib/II study on fisogatinib and CS1001 combo for treating patients with locally advanced/metastatic hepatocellular carcinoma.